BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 22484209)

  • 1. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
    Jovelet C; Bénard J; Forestier F; Farinotti R; Bidart JM; Gil S
    Eur J Pharm Sci; 2012 Aug; 46(5):484-91. PubMed ID: 22484209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib.
    Jovelet C; Deroussent A; Broutin S; Paci A; Farinotti R; Bidart JM; Gil S
    Eur J Drug Metab Pharmacokinet; 2013 Sep; 38(3):149-57. PubMed ID: 23446814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
    Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
    Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
    Azzariti A; Porcelli L; Simone GM; Quatrale AE; Colabufo NA; Berardi F; Perrone R; Zucchetti M; D'Incalci M; Xu JM; Paradiso A
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):335-46. PubMed ID: 19495754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein.
    Mi Y; Lou L
    Br J Cancer; 2007 Oct; 97(7):934-40. PubMed ID: 17912240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
    Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
    Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.
    Schneiderman RS; Shmueli E; Kirson ED; Palti Y
    BMC Cancer; 2010 May; 10():229. PubMed ID: 20492723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function.
    Zheng LS; Wang F; Li YH; Zhang X; Chen LM; Liang YJ; Dai CL; Yan YY; Tao LY; Mi YJ; Yang AK; To KK; Fu LW
    PLoS One; 2009; 4(4):e5172. PubMed ID: 19390592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein.
    Zhang FY; Du GJ; Zhang L; Zhang CL; Lu WL; Liang W
    Pharm Res; 2009 Apr; 26(4):914-25. PubMed ID: 19067124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
    Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
    Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif.
    Ye S; MacEachran DP; Hamilton JW; O'Toole GA; Stanton BA
    Am J Physiol Cell Physiol; 2008 Sep; 295(3):C807-18. PubMed ID: 18650266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro modulation of P-glycoprotein, MRP-1 and BCRP expression by mangiferin in doxorubicin-treated MCF-7 cells.
    Louisa M; Soediro TM; Suyatna FD
    Asian Pac J Cancer Prev; 2014; 15(4):1639-42. PubMed ID: 24641381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells.
    Li C; Guan X; Xue H; Wang P; Wang M; Gai X
    Pathol Res Pract; 2017 Jul; 213(7):848-853. PubMed ID: 28554760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.
    Hirayama C; Watanabe H; Nakashima R; Nanbu T; Hamada A; Kuniyasu A; Nakayama H; Kawaguchi T; Saito H
    Pharm Res; 2008 Apr; 25(4):827-35. PubMed ID: 17934801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capsaicin and Piperine Can Overcome Multidrug Resistance in Cancer Cells to Doxorubicin.
    Li H; Krstin S; Wang S; Wink M
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29498663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
    Guérin O; Etienne-Grimaldi MC; Monteverde M; Sudaka A; Brunstein MC; Formento P; Lattanzio L; Maffi M; Tonissi F; Ortholan C; Pagès G; Fischel JL; Lo Nigro C; Merlano M; Milano G
    Urol Oncol; 2013 Nov; 31(8):1567-75. PubMed ID: 22608542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ailanthone reverses multidrug resistance by inhibiting the P-glycoprotein-mediated efflux in resistant K562/A02 cells.
    Han F; Liu G; Sun C; Wei J
    Cell Mol Biol (Noisy-le-grand); 2018 Dec; 64(15):55-61. PubMed ID: 30672437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.